Study of Aritinercept for Generalized Myasthenia Gravis
This study is testing a drug called aritinercept in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. Researchers want to see how safe aritinercept is and if your body tolerates it well. They will also look at how the drug works in your body and if it helps with gMG symptoms. You may receive aritinercept or a placebo (an inactive substance). The study is open to adults aged 18 to 85 who have gMG classified as MGFA Class II-IV. You cannot join if you have had cancer recently or are pregnant or breastfeeding. The study plans to enroll 81 participants, but its current status is unclear.
- Study design
- This interventional study plans to enroll 81 participants with generalized myasthenia gravis, who will receive either aritinercept or a placebo via subcutaneous injection.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will assess safety and tolerability from the start of the study until its completion, which could be up to 73 weeks.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
At a glance
Conditions
Where it's being run
11 sites across 5 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- To assess the safety and tolerability of aritinercept: Incidence of treatment-emergent adverse eventsBaseline to study completion, up to 73 weeks